Table 1 Lists of small-molecule MDM2 inhibitors in clinical trials
Drug | Disease | Combination | Phase | Status | Trial No |
|---|---|---|---|---|---|
RG7112 (RO5045337) | Advanced solid tumors | I | Completed | NCT00559533 | |
Hematologic neoplasm | I | Completed | NCT00623870 | ||
Solid tumors | I | Completed | NCT01164033 | ||
Sarcoma | Doxorubicin | Ib | Completed | NCT01605526 | |
AML | Cytarabine | Ib | Completed | NCT01635296 | |
Sarcoma | I | Completed | NCT01143740 | ||
CML, neoplasms, AML | I | Completed | NCT01677780 | ||
RG7388 (Idasanutlin) | Advanced malignancies, except leukemia | I | Completed | NCT01462175 | |
Solid tumors | I | Completed | NCT03362723 | ||
AML | Idarubicin Daunorubicin Cytarabine | I/Ib | Completed | NCT01773408 | |
Relapsed and refractory AML | Cytarabine | III | Terminated | NCT02545283 | |
Non-Hodgkin’s lymphoma | Obinutuzumab Rituximab | I/Ib | Terminated | NCT02624986 | |
Relapsed and refractory AML | venetoclax | Ib | Completed | NCT02670044 | |
Relapsed and refractory follicular lymphoma, relapsed and refractory diffuse large B-cell lymphoma | Obinutuzumab Venetoclax Rituximab | Ib/II | Terminated | NCT03135262 | |
AML | Cytarabine Daunorubicin | Ib/II | Completed | NCT03850535 | |
Breast cancer | Atezolizumab | I/II | Terminated | NCT03566485 | |
Solid tumors | I | Completed | NCT02828930 | ||
Polycythemia vera, essential thrombocythemia | Pegasys | I | Completed | NCT02407080 | |
Neoplasms | Posaconazole | I | Completed | NCT01901172 | |
AML, acute lymphocytic leukemia, neuroblastoma, solid tumors | Cyclophosphamide Topotecan Fludarabine Cytarabine | I/II | Recruiting | NCT04029688 | |
Relapsed multiple myeloma | Ixazomib Dexamethasone venetoclax | I/II | Active, not recruiting | NCT02633059 | |
Solid tumors | Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emtansine Inavolisib Belvarafenib Pralsetinib | II | Recruiting | NCT04589845 | |
Colorectal cancer | Regorafenib Atezolizumab Imprime PGG Bevacizumab Isatuximab Selicrelumab AB928 Genetic: LOAd703 | I/II | Recruiting | NCT03555149 | |
Glioblastoma | APG101 Alectinib Atezolizumab Vismodegib Temsirolimus Palbociclib | I/II | Recruiting | NCT03158389 | |
AMG232 (KRT-232) | Advanced solid tumors, multiple myeloma | I | Completed | NCT01723020 | |
AML | Trametinib | I | Completed | NCT02016729 | |
Metastatic melanoma | Trametinib Dabrafenib | Ib/IIa | Completed | NCT02110355 | |
AML, relapsed and refractory AML | Decitabine | I | Suspended | NCT03041688 | |
Soft tissue sarcoma | Radiation therapy | Ib | Recruiting | NCT03217266 | |
Polycythemia vera | Ruxolitinib | II | Active, not recruiting | NCT03669965 | |
Relapsed multiple myeloma | Carfilzomib Dexamethasone Lenalidomide | I | Recruiting | NCT03031730 | |
Brain cancer | Radiation therapy | I | Suspended | NCT03107780 | |
AML | Cytarabine Idarubicin HCI | Ib | Recruiting | NCT04190550 | |
APG-115 (AA-115) | Advanced solid tumors, lymphomas | I | Completed | NCT02935907 | |
Metastatic melanomas, advanced solid tumors | Pembrolizumab | Ib/II | Recruiting | NCT03611868 | |
Salivary gland carcinoma | Carboplatin | I/II | Recruiting | NCT03781986 | |
AML, acute lymphocytic leukemia, neuroblastoma | Azacitidine Cytarabine | Ib | Recruiting | NCT04275518 | |
AML | 5-Azacitidine | Ib/II | Recruiting | NCT04358393 | |
Liposarcoma, advanced solid tumors | Toripalimab | Ib/II | Recruiting | NCT04785196 | |
T-prolymphocytic leukemia | APG-2575 | IIa | Recruiting | NCT04496349 | |
CGM-097 | Advanced solid tumors with TP53wt | I | Completed | NCT01760525 | |
HDM201 | Liposarcoma | Ribociclib | Ib/II | Completed | NCT02343172 |
Uveal melanoma | LXS196 | I | Completed | NCT02601378 | |
Advanced solid and hematological TP53wt tumors | Ancillary treatment | I | Completed | NCT02143635 | |
AML | I/II | Withdrawn | NCT03760445 | ||
Advanced/metastatic colorectal cancer | Trametinib | I | Recruiting | NCT03714958 | |
Myelofibrosis | Ruxolitinib | I/II | Recruiting | NCT04097821 | |
Colorectal cancer, nonsmall cell lung carcinoma, triple negative breast cancer, renal cell carcinoma | Spartalizumab | I | Completed | NCT02890069 | |
Malignant solid tumors | Ribociclib | II | Recruiting | NCT04116541 | |
AML | Midostaurin | I | Recruiting | NCT04496999 | |
AML, myelodysplastic syndromes | MBG453 | Ib | Recruiting | NCT03940352 | |
DS-3032b (Milademetan) | Advanced solid tumors, lymphomas | I | Completed | NCT01877382 | |
Relapsed and refractory AML | I | Completed | NCT03671564 | ||
AML | Quizartinib | I | Terminated | NCT03552029 | |
AML, myelodysplastic syndromes | 5-Azacitidine | I | Terminated | NCT023199369 | |
AML, relapsed and refractory AML | Cytarabine Venetoclax | I/II | Completed | NCT03634228 | |
Myeloma | I | Terminated | NCT02579824 | ||
SAR405838 | Neoplasm malignant | Pimasertib | I | Completed | NCT01985191 |
Neoplasm malignant | I | Completed | NCT016636479 | ||
MK-8242 | AML | Cytarabine | I | Terminated | NCT01451437 |
Solid tumors | I | Terminated | NCT01463696 |